ArticleAmerican journal of nuclear medicine and molecular imaging2023
Uterine adenosarcoma: a case report and review of the literature.
Article in American journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 11 citations in OpenAlex.
- Article
- Müllerian adenosarcoma in a young adult: A case report and literature review of diagnostic and management challenges.Gynecologic oncology reports · 2026Article
- A case report of uterine adenosarcoma with sarcomatous overgrowth and pulmonary metastasis.Frontiers in oncology · 2026Article
- Adenosarcoma of the uterine cervix - a novel case report and review of the literature.Przeglad menopauzalny = Menopause review · 2025Article
- Differentiating uterine adenosarcoma from endometrial polyps: MRI imaging features.Abdominal radiology (New York) · 2025Article
- A Rare Case of Endometrial Adenosarcoma and Its Management: A Case Report and Literature Review.Cureus · 2025Article
- Article
- Genomics of uterine malignancies and the potential of precision medicine.Therapeutic advances in medical oncology · 2025Review
- Survival Trends for Uterine Sarcomas from a Tertiary Center: The Oxford Experience.Diseases (Basel, Switzerland) · 2024Article
- Uterine adenosarcoma presenting as uterine inversion: A case study.Gynecologic oncology reports · 2024Article
- A rare case report of endometrial adenosarcoma in the cesarean scar diverticulum.Translational cancer research · 2024Article
- Mullerian adenosarcoma of the uterus with MASO: a case report of cervical adenosarcoma in a young female that never had sexual behavior.BMC women's health · 2024Article
- The uterine adenosarcoma with postoperative residual in a woman treated by total abdominal hysterectomy/bilateral salpingo-oophorectomy: A case report and review of literature.Cancer reports (Hoboken, N.J.) · 2023Review
- Next-Generation Sequencing Analysis of 3 Uterine Adenosarcomas with Heterogeneously Differentiated Genomic Mutations.International journal of analytical chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine adenosarcoma is a rare gynecological malignancy with no specific symptoms, and the optimal management is still inconclusive. Herein we present a case of uterine adenosarcoma in a 38-year-old woman with a good prognosis and review of literatures. The patient presented with abnormal vaginal bleeding with no special medical history. Sonographic scan revealed a heterogeneous echoic mass in the cavity, indicating a polypus or a submucous myoma. The pathology based on the specimen after the hysteroscopic tumor excision suggested diagnosis of uterine adenosarcoma. Subsequently, the patient received pelvic MRI scan before surgery. MRI identified a patchy lesion at the cervix-lower endometrial cavity with low signal in T1WI and a mixed high T2 signal in T2WI, with no sign of metastasis. Then total abdominal hysterectomy with bilateral salpingo-oopherectomy plus pelvic lymph node dissection was performed and 6 cycles of chemotherapy were administered. The patient remains disease-free on follow-up to date, more than 15 months after chemotherapy.
Indexed as
Identifiers
37214266PMC10193199W4377565690What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.